Excluded studies

Excluded studies

Study reference

Reason for exclusion

Dauvilliers Y (2014) Novel therapeutic approach in narcolepsy: Clinical trials of an antagonist/inverse agonist of the histamine H3 receptor. Journal of sleep research 23: 75 (282)

Abstract only

Duplicate of included study (HARMONY 1)

Leu-Semenescu S, Nittur N, Golmard JL et al. (2014) Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review. Sleep Medicine 15: 681–7

Poor relevance against search terms

Not licensed indication

The European Public Assessment Report (EPAR) for pitolisant states that the narcolepsy development programme included 5 phase III trials, of which HARMONY I and HARMONY Ibis were considered pivotal for the indication in the treatment of narcolepsy with or without cataplexy.